Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.K. Coverage Rejection Of Alimta In NSCLC Increases Concerns About Access To Cancer Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K.’s NICE has rejected reimbursement under the National Health Service for Lilly’s Alimta in non-small cell lung cancer on cost grounds, prompting renewed calls to update or replace the U.K. Cancer Drugs Fund.


Related Content

European Notebook: Industry’s Post-EU Election Goals; IMI2 Gets Under Way; FDA/EMA Tie-Up On Childhood Gaucher Studies
NICE Sends Out Cost Warning By Flatly Rejecting Kadcyla On Price
NICE On Alimta, Pixuvri Ups Concerns It Prefers Cost Over Clinical Efficacy
Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink
Lilly’s Alimta Gets UK Recommendation As Mesothelioma Therapy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts